Risk stratification frameworks guide NMIBC management, with intermediate-risk patients requiring nuanced decision-making due to high recurrence rates. The BCG shortage has increased reliance on ...
Intravesical therapy plays a crucial role in reducing the risk of recurrence and progression in patients with non-muscle invasive bladder cancer (NMIBC). Among the most widely used intravesical ...
PRINCETON, N.J., Oct. 02, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company focused on developing and commercializing innovative solutions for urothelial and specialty ...
Sandip M. Prasad, MD, MPhil, shares his thoughts on the impact of the FDA approval of mitomycin for intravesical solution for patients with LG-IR-NMIBC. Mitomycin for intravesical solution (Zusduri; ...
New data showed a 72.2% DOR rate in patients with recurrent low-grade, intermediate-risk non–muscle-invasive bladder cancer who had a CR at 3 months. Updated data from the phase 3 ENVISION trial ...
PRINCETON, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative treatments for urothelial and specialty ...
New trials target hard-to-treat cancers with more personalized, less toxic therapies, including pediatric brain tumors, colorectal, ovarian, bladder cancers, and leukemia. FDA cleared Reyobiq for ...
Zusduri is expected to be available on or around July 1, 2025. The Food and Drug Administration (FDA) has approved Zusduri (mitomycin intravesical solution) for adults with recurrent low-grade ...
PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback